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Abstract
Introduction:  Liver  transplantation  is  the  best  therapeutic  option  for  end-stage  liver  disease.
Non-selective  beta-blocker  medications  such  as  propranolol  act  directly  on  the  cardiovascular
system and  are  often  used  in  the  prevention  of  gastrointestinal  bleeding  resulting  from  HP.  The
effects of  propranolol  on  cardiovascular  system  of  cirrhotic  patients  during  liver  transplantation
are not  known.
Objective:  Evaluate  the  inﬂuence  of  propranolol  used  preoperatively  on  cardiac  index  during
the anhepatic  phase  of  liver  transplantation.
Method:  101  adult  patients  (73  male  [72.2%])  who  underwent  cadaveric  donor  orthotopic  liver
transplantation  by  piggyback  technique  with  preservation  of  the  retrohepatic  inferior  vena  cava
performed at  Hospital  das  Clinicas,  Federal  University  of  Minas  Gerais  were  evaluated.  There
was no  difference  in  severity  between  groups  by  the  MELD  system,  p  =  0.70.  The  preoperative
use of  propranolol  and  the  cardiac  index  outcome  were  compared  during  the  anhepatic  phase
of liver  transplantation  in  5  groups  (I:  increased  cardiac  index,  II:  cardiac  index  reduction  lower
than 16%,  III:  cardiac  index  reduction  equal  to  or  greater  than  16%  and  less  than  31%,  IV:  cardiac
index reduction  equal  to  or  greater  than  31%  and  less  than  46%,  V:  cardiac  index  reduction  equal
to or  greater  than  46%).
Results:  Patients  in  group  I  (46.4%)  who  received  propranolol  preoperatively  were  statistically
similar to  groups  II  (60%),  III  (72.7%),  IV  (50%)  and  V  (30.8%),  p  =  0.57.
Conclusion:  The  use  of  propranolol  before  transplantation  as  prophylaxis  for  gastrointestinal
bleeding  may  be  considered  safe,  as  it  was  not  associated  with  worsening  of  cardiac  index  in
anhepatic phase  of  liver  transplantation.a  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights© 2014  Sociedade  Brasileir
reserved.∗ Corresponding author.
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Inﬂuência  do  propranolol  pré-operatório  no  índice  cardíaco  durante  a  fase  anepática
do  transplante  hepático
Resumo
Introduc¸ão:  O  transplante  hepático  (TH)  é  a  melhor  opc¸ão terapêutica  para  doenc¸a  hepática  em
estágio terminal  (DHET).  As  medicac¸ões  betabloqueadoras  não  seletivas,  como  o  propranolol,
atuam diretamente  no  sistema  cardiovascular  (SCV)  e  são  frequentemente  usadas  na  prevenc¸ão
de hemorragia  digestiva  decorrente  da  HP.  Os  efeitos  do  propranolol  no  SCV  de  cirróticos  durante
o TH  não  são  conhecidos.
Objetivo:  Avaliar  a  inﬂuência  do  uso  pré-operatório  do  propranolol  no  índice  cardíaco  (IC)
durante a  fase  anepática  do  TH.
Método:  Avaliaram-se  101  pacientes  adultos  (73  homens,  72,2%)  submetidos  a  transplante
ortotópico  de  fígado  doador  cadáver,  pela  técnica  de  piggyback  com  preservac¸ão  da  veia  cava
inferior retro-hepática,  feito  no  Hospital  das  Clínicas  da  Universidade  Federal  de  Minas  Gerais.
Não houve  diferenc¸a  de  gravidade  pelo  sistema  MELD  entre  os  grupos,  p  =  0,70.  Foram  compara-
dos o  uso  pré-operatório  de  propranolol  com  o  desfecho  do  IC  durante  a  fase  anepática  do  TH
em cinco  grupos  (I:  aumento  do  IC;  II:  reduc¸ão  do  IC  inferior  a  16%;  III:  reduc¸ão  do  IC  igual  a  ou
maior do  que  16%  e  menor  do  que  31%;  IV:  reduc¸ão  do  IC  igual  a  ou  maior  do  que  31%  e  menor
do que  46%;  V:  reduc¸ão  do  IC  igual  a  ou  maior  do  que  46%).
Resultados:  Pacientes  que  ﬁzeram  uso  pré-operatório  de  propranolol  no  grupo  I (46,4%)  foram
estatisticamente  semelhantes  aos  dos  grupos  II  (60%),  III  (72,7%),  IV  (50%)  e  V  (30,8%),  p  =  0,57.
Conclusão: O  propranolol  no  pré-transplante,  como  proﬁlaxia  para  hemorragia  digestiva,  pode
ser considerado  seguro,  pois  não  se  associou  à  pioria  do  IC  na  fase  anepática  do  TH.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Since  the  ﬁrst  liver  transplantation  (LT)  performed  in
humans  by  Starzl  in  Denver,  USA,  in  1963,  major  advances
such  as  better  preservation  of  organs,  improvement  of
surgical  techniques,  better  knowledge  of  anesthesiology,
and  immunosuppressive  therapy  evolution  have  made  liver
transplantation  the  best  treatment  option  for  end-stage
liver  disease  (ESLD).1 Currently,  post-LT  survival  is  approxi-
mately  90%,  85%  and  80%  at  1,  3  and  5  years,  respectively.2
Cirrhosis  is  the  most  common  cause  of  portal  hyperten-
sion  (PH)  and  causes  increase  in  both  intrahepatic  vascular
resistance  and  portal  ﬂow.  PH  is  associated  with  serious
complications,  such  as  ascites,  hepatic  encephalopathy,  and
bleeding  from  esophagogastric  varices.3 The  hepatic  venous
pressure  gradient  (HVPG)  reduction  below  12  mmHg  is  essen-
tial  to  minimize  the  risk  of  upper  gastrointestinal  bleeding
in  patients  with  PH.  Non-selective  beta-blockers  drugs,  such
as  propranolol  and  pindolol,  reduce  PH  by  decreasing  the
cardiac  output  (CO)  and  splanchnic  vasoconstriction  and,
thus,  the  portal  blood  ﬂow.3--5 The  pharmacological  effects
of  beta-blockers  interfere  with  the  cardiovascular  system
(CVS)  during  the  perioperative  period  of  LT  and  affect  the
transplanted  liver  functionality.6
LT  intraoperative  period  is  classically  divided  into  three
phases:  pre-anhepatic,  anhepatic,  and  neohepatic.  During
the  anhepatic  phase,  severe  hemodynamic  changes  may
occur  and  it  is  important  that  the  anesthesiologist  be  pre-
pared  to  optimize  this  patient  during  graft  reperfusion,  a
critical  time  with  a  high  incidence  of  CVS  instability.7
w
t
aThus,  it  is  important  to  know  the  effects  of  preoperative
ropranolol  during  LT.
bjectives
valuate  the  effect  of  preoperative  use  of  propranolol  and
I  clinical  and  surgical  variables  during  the  anhepatic  phase
f  orthotopic  transplantation  of  cadaver  donor  orthotopic
iver  transplantation.
ethod
rospective  study  was  performed  at  the  Gastroenterology
lfa  Institute  of  the  Hospital  das  Clinicas,  Federal  Uni-
ersity  of  Minas  Gerais  (HC-UFMG).  This  research  was
pproved  by  the  Research  Ethics  Committee  of  UFMG,  CAAE
244.0.203.000-08  and  CAAE  0406.0.203.000-11  projects.
During  the  study  period,  from  August  29,  2008  to  January
,  2012,  218  liver  transplants  were  performed,  wherein  13
f  them  are  of  retransplantation.  A  total  of  114  patients,
ho  agreed  with  and  signed  the  informed  consent  after  the
nvitation  to  participate,  met  the  inclusion  criteria.  Thir-
een  patients  were  excluded  because  of  hemodynamic  data
ollection  failure.Inclusion  criteria  were  age  ≥18  years,  transplantation
ith  cadaver  donor  by  piggyback  technique,  and  signing
he  informed  consent.  Exclusion  criteria  were  previous  LT
nd  hepatectomy,  preoperative  hemodynamic  instability
1 E.  Seiberlich  et  al.
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Table  1  Descriptive  analysis  of  patients’  variables.
Variables  (n  =  101)
Mean  (±SD)
Meld  18.07  (±5.64)
Age  50.57  (±10.43)
Weight  (kg)  75.43  (±16.49)
Height  (m)  168.37  (±9.5)
BMI  (kg  m−2)  26.51  (±4.86)
CI T2  (L  min−1 m−2)  4.2  (±1.6)
SVRI  T2  (dyne  s  cm−5 m−2)  1276  (±521)
MAPm  (mmHg) 67.6  (±16.9)
CVPm  (mmHg) 7.8  (±3.4)
Noradrenaline  (mcg  kg−1 min−1) 0.38  (±0.52)
CI T3  (L  min−1 m−2)  3.50  (±1.56)
SVRI  T3  (dyne  s  cm−5 m−2)  1668  (±979)
CI  (%)  −14.3  (±30.3)
T2/T3  (min)  118.4  (±37.7)
All data are presented as mean (±standard deviation). Meld,
model for end-stage liver disease; BMI, body mass index; CI T2,
cardiac index at the beginning of anhepatic phase; SVRI T2, sys-
temic vascular resistance index in early anhepatic phase; MAPm,
average mean arterial pressure during anhepatic phase; CVPm,
mean central venous pressure during anhepatic phase; CI T3,
cardiac index at the end of anhepatic phase; SVRI T3, systemic
vascular resistance index at the end of anhepatic phase; CI,
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haracterized  by  the  need  for  vasopressor  agents,  acute
iver  failure,  and  autoimmune  hepatitis.
One  hundred  and  one  patients  participated  in  the  study,
3  male  (72.2%).  LT  indications  were:  post-viral  C  cirrho-
is  (33.7%),  ethanol  cirrhosis  (28.7%),  cryptogenic  cirrhosis
20.8%),  post-viral  B  cirrhosis  (6.9%),  primary  biliary  cir-
hosis  (3.9%),  and  others  (5.9%).  Fifty-four  patients  were
eceiving  beta-blockers  in  the  pretransplant  period  (53.5%),
nd  propranolol  was  the  drug  used  for  prophylaxis  of  gastro-
sophageal  varices  bleeding.3
The  study  patients  underwent  balanced  general  anesthe-
ia.  Anesthesia  was  induced  with  etomidate  (0.3  mg  kg−1),
entanyl  (5  g  kg−1),  and  rocuronium  (1.2  mg  kg−1),  main-
ained  with  isoﬂurane  (1  MAC),  and  monitored  by  the
nesthetic  gas  analyzer.  Additional  doses  of  rocuronium  and
entanyl  were  used  as  needed.
Before  surgical  incision,  all  patients  underwent  the  fol-
owing  monitoring:  intra-arterial  pressure  by  radial  artery
atheterization,  pulmonary  artery  pressures,  pulmonary
rtery  occlusion  pressure,  and  continuous  cardiac  out-
ut  using  the  Swan-Ganz  DDC-Edwards® catheter  and
igilance-Edwards® monitor.  Data  included  intra-arterial
ean  pressure  (IAP),  central  venous  pressure  (CVP),  mean
ulmonary  artery  pressure  (PAP),  pulmonary  capillary  pres-
ure  (PCP),  heart  rate  (HR),  and  cardiac  output  (CO).  In
ddition  to  the  hemodynamic  data  the  dosage  of  vasopressor
rugs  used  in  intraoperative  was  recorded.
Measurements  were  performed  at  the  following  times:
nduction  of  anesthesia  (T1);  beginning  of  anhepatic  phase
haracterized  as  the  portal  vein  clamping  (T2);  5  min  before
raft  reperfusion,  characterized  as  the  end  of  anhepatic
hase  (T3).  In  this  study  the  time  between  T2  and  T3  was
onsidered  the  anhepatic  phase  duration.
From  collected  data,  the  body  surface  area  (BSA),  periph-
ral  vascular  resistance  index  (PVRI),  and  CI  were  calculated
sing  the  Vigilance-Edwards® monitor.  Body  mass  index  (BMI)
as  calculated  using  the  following  formula:  BMI  =  weight
kg)  ×  height  (m)−2.  The  Meld  (model  for  end-stage  liver
isease)  used  in  this  study  was  the  calculated  and  not  the
orrected  Meld.
According  to  the  percentage  change  in  CI,  occurring
etween  the  beginning  (T2)  and  the  end  (T3)  of  the  anhep-
tic  phase,  and  the  severity  of  myocardial  impairment
unction,  the  patients’  results  were  divided  into  ﬁve  groups:
roup  I:  increased  CI;  Group  II:  CI  reduction  lower  than  16%;
roup  III:  CI  reduction  equal  to  or  greater  than  16%  and  less
han  31%;  Group  IV:  CI  reduction  equal  to  or  greater  than
1%  and  less  than  46%;  and  Group  V:  CI  reduction  equal  to  or
reater  than  46%).  Groups  II,  III,  IV,  and  V  had  an  unfavorable
utcome  of  cardiac  index.
tatistical  analysis
PSS  version  18  was  the  software  used  in  the  analysis.  The
eference  level  of  signiﬁcance  in  univariate  analysis  was
.20.  In  the  multivariate  analysis,  a  0.05  signiﬁcance  level
as  considered.
Shapiro--Wilk  normality  test  was  used  for  continuous
ariables  in  order  to  decide  for  parametric  or  non-
arametric  tests  in  data  analysis.
S
m
b
dcardiac index variation between the beginning and end of anhep-
atic phase; T2/T3, time of anhepatic phase.
In  the  descriptive  analysis,  continuous  variables  were
xpressed  as  mean  values  and  standard  deviations  and  cat-
gorical  variables  as  frequency  and  percentage.
For  comparison  of  continuous  variables  in  the  ﬁve  inde-
endent  groups  (I,  II,  III,  IV,  and  V),  the  mean  comparison
est  ANOVA  was  used  when  the  variables  had  normal  Gauss-
an  distribution  and  the  Kruskal--Wallis  test  for  median
omparison  when  the  variables  did  not  reach  Gaussian
istribution.
To  evaluate  the  association  of  categorical  variables  in
he  ﬁve  groups,  the  linear  trend  chi-square  test  was  used
ecause  in  this  case  the  groups  have  an  importance  of
rdering.
esults
escriptive  analysis  of  the  patients’  clinical  characteristics
s  shown  in  Table  1.
Table  2  shows  the  frequency  and  percentage  of  some
ategorical  variables.
Table  3  shows  the  association  between  categorical  varia-
les  and  CI  variation  in  the  different  groups.
Table  4  shows  the  association  between  continuous  varia-
les  with  CI  variation  in  different  groups.
iscussionince  the  development  of  propranolol  by  James  Black8 for
ore  than  four  decades,  the  adrenergic  beta-blockers  have
een  used  for  treatment  of  hypertension,  coronary  artery
isease,  myocardial  infarction,  and  heart  failure,  standing
Inﬂuence  of  preoperative  propranolol  on  cardiac  index  during  th
Table  2  Characteristic  of  study  population  in  frequency
and percentage.
Variable  (n  =  101)
Sex  (male)  73  (72.3%)
Hepatocellular  carcinoma  (yes)  22  (21.8%)
Preoperative  beta-blocker  (yes)  54  (53.5%)
Noradrenaline  T3  (yes)  65  (64.4%)
Temporary  portocaval  anastomosis  (yes)  16  (15.8%)
Groups
I 28  (27.7%)
II 20  (19.8%)
III 22  (21.8%)
IV 18  (17.8%)
V 13  (12.9%)
All data are presented in frequency (percentage). T3, end of
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danhepatic phase.
out  mainly  by  the  action  on  beta-adrenergic  receptors  in
the  CVS.  In  the  heart,  beta-1  receptors  are  present  in  the
sinoatrial  node  (speeding  depolarization),  cardiac  muscle
(increasing  contractility),  and  transmission  tissue  (increas-
ing  conduction  velocity)  and  determine  increase  in  cardiac
output.  Beta-2  receptors  act  on  the  peripheral  vascular
muscle  (causing  vasodilation).9 In  drug  prevention  of  upper
gastrointestinal  bleeding  by  esophagogastric  varices  in
patients  with  PH,  the  beta-blocker  is  indicated  at  low  initial
doses  (propranolol  20  mg  day−1)  with  a  progressive  increase
according  to  patient  tolerance  and  HR  reduction.10
Systolic  ventricular  function  is  determined  by  preload,
afterload,  and  myocardial  contractility  ----  factors  that  affect
the  CI.  During  preoperative  evaluation  of  ESLD  patients  CVS
should  be  considered  because  terminal  liver  disease  may  be
associated  with  cirrhotic  cardiomyopathy.  In  these  patients,
CO  might  be  increased  due  to  reduced  afterload  even  in  the
presence  of  contractile  dysfunction.  However,  when  the  CVS
is  highly  demanded  as  during  LT  the  myocardial  dysfunction
may  manifest  and  cardiac  response  may  be  unsatisfactory
11and  determine  an  unfavorable  outcome. Wong  et  al.,
evaluating  myocardial  function  of  asymptomatic  cirrhotic
patients  for  cardiovascular  disease  during  exercise  found  a
smaller  increase  in  CO  compared  with  control.  The  decrease
i
i
(
Table  3  Association  of  categorical  variables  with  the  ﬁve  groups
I  (n  =  28)  II  (n  =
Sex  (male)  21  (75)  13  (6
Hepatocellular  carcinoma  (yes)  5  (17.9)  4  (2
Beta-blocker  (yes)  13  (46.4)  12  (6
Noradrenaline  T3  (yes)  19  (67.9)  12  (6
Temporary portocaval  anastomosis  (yes)a 2  (7.1)  2  (1
All data are presented in frequency (percentage). T3, end of anhepatic
trend.
a Fisher’s exact attest.e  anhepatic  phase  173
n  cardiac  performance  has  as  factors  left  ventricular  hyper-
rophy,  diastolic  dysfunction,  and  reduced  chronotropic
esponse.12 In  this  study,  we  evaluated  the  CI  variation
uring  LT  anhepatic  phase  which  is  a  very  demanding  period
or  the  CVS,  in  order  to  ﬁnd  preoperative  factors  that  may
e  associated  with  an  unfavorable  outcome,  which  is  the
orsening  of  myocardial  performance.
The  classical  technique  of  LT  involves  the  donor  hepa-
ectomy  with  retrohepatic  vena  cava  resection  associated
ith  temporary  occlusion  of  the  portal  and  cava  veins  dur-
ng  the  anhepatic  phase,  which  causes  decreased  venous
eturn  to  the  heart,  decreased  renal  perfusion,  and  conges-
ion  of  the  splanchnic  venous  system  in  this  phase.13 During
he  surgical  procedure,  to  avoid  interference  of  the  tech-
ique  used  on  the  analyzed  data,  we  included  only  the  LT
erformed  with  the  piggyback  technique,  in  which  there  is
reservation  of  the  inferior  vena  cava.  Even  with  the  piggy-
ack  technique,  the  portal  vein  needs  to  be  occluded  causing
ncreased  portal  pressure  with  splanchnic  bed  congestion
nd  intestinal  edema.  In  1993,  Tzakis  et  al.  described  the
se  of  piggyback  technique  with  the  placement  of  tempo-
ary  portocaval  shunt  (TPCS)  for  portal  vein  communication
ith  the  infrahepatic  inferior  vena  cava  during  the  anhep-
tic  phase.14 Figueras  et  al.,  in  order  to  assess  whether
PCS  would  improve  the  hemodynamic  and  metabolic  evolu-
ion  during  LT  with  piggyback  technique,  found  an  improved
emodynamic  proﬁle  with  less  need  for  blood  products  in
PCS  group,  but  this  beneﬁt  was  more  evident  in  a  sub-
roup  of  patients  with  portal  ﬂow  exceeding  1000  mL  min−1
r  portocaval  gradient  greater  than  or  equal  to  16  mmHg.13
argarit  et  al.15 evaluated  the  advantages  of  TPCS  during  LT
nd  concluded  that  TPCS  during  the  anhepatic  phase  reduces
he  need  for  packed  red  blood  cell  transfusion  and  improves
ostoperative  renal  function,  only  in  patients  with  portal
ein  ﬂow  exceeding  800  mL  min−1. Muscari  et  al.,16 evaluat-
ng  84  patients  undergoing  LT  with  the  piggyback  technique,
oncluded  that  the  routine  use  of  TPCS  is  not  justiﬁed.  In
he  present  study,  TPCS  was  performed  during  the  anhep-
tic  phase  in  only  15.8%  of  patients  (Table  2),  and  there  was
o  association  between  TPCS  and  percentage  change  in  CI
uring  anhepatic  phase  (Table  3).Table  4  shows  that  some  moderating  variables  that  could
nﬂuence  the  outcome  were  controlled.  Important  factors
n  this  evaluation  were  the  duration  of  anhepatic  phase
T2/T3),  which  could  be  increased  by  surgical  difﬁculty.
 of  cardiac  index  variation  in  the  anhepatic  phase.
Groups  (n  =  101)  p
 20)  III  (n  =  22)  IV  (n  =  18)  V  (n  =  13)
5)  15  (68.2)  13  (72.2)  11  (84.6)  0.616
0)  5  (22.7)  4  (22.2)  4  (30.8)  0.387
0)  16  (72.7)  9  (50)  4  (30.8)  0.575
0)  15  (68.2)  9  (50)  10  (76)  0.951
0)  6  (27.3)  3  (16.7)  3  (23.1)  0.292
 phase; beta-blocker, preoperative use. Chi-square test for linear
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Table  4  Association  of  continuous  variables  with  the  ﬁve  groups  of  cardiac  index  variation  in  the  anhepatic  phase.
Group  (n  =  101)  p
I  (n  =  28)  II  (n  =  20)  III  (n  =  22)  IV  (n  =  18)  V  (n  =  13)
Meld  18.7  (8.5--40.6)  16.5  (6.4--24.3)  17.8  (6.4--26.2)  17.8  (7.8--30.4)  20.0  (7.8--34.1)  0.701
Age (years)  50.8  (29.5--67.2)  51.5  (20.3--66.0)  51.6  (31.8--62.7)  55.1  (18.8--66.6)  46.3  (29.4--66.9)  0.281
Weight (kg)  78.5  (55--105)  79.9  (48--103)  73  (45.8--93)  70  (52.5--133.5)  76  (47--113)  0.784
Height (cm)a 168.7  (±8.2)  165.85  (±9.0)  166.62  (±10.8)  170.39  (±9.7)  171.92  (±10.2)  0.335
BMI (kg  m−2)  27.2  (18.7--34.1)  27.1  (19.1--36.3)  25.9  (19.3--30.3)  25.0  (19.5--45.9)  27.4  (19.6--34.1)  0.552
CVPm (mmHg)a 8.3  (±3.3)  8.8  (±3.4)  7.1  (±3.7)  6.9  (±2.9)  7.6  (±3.1)  0.314
MAPm (mmHg)  69  (40--105)  74  (41--115)  61  (40--133)  65  (36--100)  57  (41--117)  0.211
T2/T3 (min)a 117.9  (±41.5)  128.0  (±35.7)  109.6  (±35.7)  127.61  (±41.6)  107.15  (28.1)  0.319
Meld, model for end-stage liver disease; BMI, body mass index; CVPm, mean central venous pressure during anhepatic phase; MAPm, average mean arterial pressure during anhepatic
phase; T2/T3, duration of anhepatic phase. Data are presented as median (minimum-maximum) Kruskal--Wallis test, except the data.
a presented as mean (±standard deviation) ANOVA-test.
g  th
R
1
1
1
1
1
1
1
1
1
1Inﬂuence  of  preoperative  propranolol  on  cardiac  index  durin
The  CVPm,  which  could  be  inﬂuenced  by  partial  clamping
of  vena  cava  with  the  piggyback  surgical  technique  and
inﬂuence  CI,  was  statistically  similar  in  all  groups  evalu-
ated.  Raval  et  al.,  in  a  review  article,  reported  that  ESLD
patients  with  compromised  systolic  and  diastolic  function
not  observed  at  rest,  but  during  periods  of  high  demand,
which  reduces  the  CI  by  compromising  the  contractile
function,  diastolic  relaxation,  and  myocardial  electrophysi-
ological  conduction.  These  changes  in  cirrhotic  patients  are
known  as  cirrhotic  cardiomyopathy  and  are  directly  related
to  the  ESLD  severity.17 In  our  study,  based  on  Meld  sys-
tem,  all  groups  were  statistically  similar  and  showed  that
there  was  no  interference  of  the  liver  disease  severity  on
CI.
In  a  review  article  of  the  pathophysiology  and  clin-
ical  implications  of  cirrhotic  cardiomyopathy,  Yang  and
Lin  reported  the  importance  of  beta-adrenergic  recep-
tors  for  heart  contractile  function  and  the  involvement  of
these  receptors  in  ESLD  patients.18 Zenghua  et  al.,  in  an
experimental  study,  concluded  that  myocardial  contractil-
ity  in  response  to  beta-adrenergic  receptor  stimulation  was
attenuated  in  cirrhotic  rats  due  to  decreased  density  asso-
ciated  with  the  signaling  pathway  involvement  of  these
receptors.19 Villas-Boas  et  al.,  studying  the  effects  of  pro-
pranolol  on  renin-angiotensin  system  in  cirrhotic  patients,
reported  changes  in  hemodynamic  parameters  with  reduced
CI  in  LT  pre-anhepatic  phase  in  patients  treated  with  pro-
pranolol  preoperatively.20 Aiming  at  evaluating  the  effect
of  propranolol  on  myocardial  function  during  the  anhep-
atic  phase,  we  correlated  the  patients  receiving  propranolol
with  CI  change  during  the  anhepatic  phase  and  found  no
statistically  signiﬁcant  association  (Table  3).  The  propra-
nolol  dose  of  our  patients  ranged  from  20  mg  to  120  mg
day.  The  clinical  condition  of  ESLD  patients  rarely  allows
improved  administration  of  the  adrenergic  beta-blocker
medication.10 Non-interference  of  propranolol  on  CI  varia-
tion  may  be  due  to  the  preoperative  dose  be  considered  low,
so  there  is  signiﬁcant  beta-adrenergic  receptor  blockade  in
the  heart  and  myocardial  contractile  function  impairment
in  this  moment  of  myocardial  stress,  which  is  the  anhepatic
phase.
We  believe  that  myocardial  depression  during  the  anhep-
atic  phase  may  occur  due  to  pro-inﬂammatory  cytokine
accumulation,21 occurred  during  the  LT  and  intensiﬁed  at  the
end  of  this  phase,  associated  with  latent  cirrhotic  cardiomy-
opathy.  This  association  between  inﬂammatory  cytokine  and
worsening  of  myocardial  performance  has  been  studied  in
septic  shock,22,23 which  can  bring  substrate  for  a  future
understanding  of  this  event  in  LT.
Conclusion
The  use  of  propranolol  in  cirrhotic  liver  pre-transplantation
for  prophylaxis  of  bleeding  by  esophagogastric  varices  is
safe  for  CVS  during  the  anhepatic  phase  of  liver  transplan-
tation.Conﬂicts of interest
The  authors  declare  no  conﬂicts  of  interest.
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